Pain Inflammation and Cannabis in HIV

Conditions

• Cannabis
• HIV Infections
• Neuropathic Pain

Eligibility Criteria

Sex

ALL

Age

18 Years - 100 Years

Healthy Volunteers

Not accepted

Interventions

• Receipt of Coupon for Placebo Soft-Gel Capsule — OTHER
  The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Placebo (0:0) Softgel, 0mg THC and 0mg CBD per cap, Bottle of 30 caps
• Receipt of Coupon for High THC Soft-Gel Capsule — OTHER
  The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Vireo Yellow (6:1) Softgel, 4.29mg THC and 0.72mg CBD per cap, Bottle of 30 caps
• Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule — OTHER
  The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Vireo Green (1:1) Softgel, 2.5mg THC and 2.5mg CBD per cap, Bottle of 30 caps
• Receipt of Coupon for High CBD Soft-Gel Capsule — OTHER
  The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Vireo Indigo (1:19) Softgel, 0.25mg THC and 4.75mg CBD per cap, Bottle of 30 caps

Study Details

This study will examine how medical cannabis use affects neuropathic pain, inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain. The investigators will observe how varying ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD) in medical cannabis impact neuropathic pain, inflammation and adverse events.

Key Dates

Start date

Oct 28, 2022

Status verified

Oct 2025

Primary completion

May 3, 2024

Completion

May 3, 2024

Study Design

Enrollment

35 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Other: Coupon for a Discounted Placebo Product
  We will observe participants who were previously randomized to a coupon for discounted placebo soft-gel capsules by our collaborators, Vireo.
• Other: Coupon for a Discounted High THC Product
  We will observe participants who were previously randomized to a coupon for discounted 4.29 mg THC/0.72 mg CBD soft-gel capsules by our collaborators, Vireo.
• Other: Coupon for a Discounted Equal THC and CBD Product
  We will observe participants who were previously randomized to a coupon for discounted 2.5 mg THC/2.5 mg CBD soft-gel capsules by our collaborators, Vireo.
• Other: Coupon for a Discounted High CBD Product
  We will observe participants who were previously randomized to a coupon for discounted 0.25 mg THC/4.75 mg CBD soft-gel capsules by our collaborators, Vireo.

Primary Outcome Measure

Change in Pain Severity Score [ Time Frame: At weekly intervals from Baseline to 14 weeks ]

Locations (1)

Find similar trials in The Bronx, NY

Related Studies

• WiseApp for Spanish Speakers Living With HIV
  Recruiting · Columbia University · New York, New York
• Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection
  Enrolling By Invitation · Hunter College of City University of New York · Ann Arbor, Michigan
• Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples
  Recruiting · Hunter College of City University of New York · Detroit, Michigan
• Virtual Reality (VR) Self-Hypnosis Software
  Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York